Floatz Rating
B56/100
Confidence
Indicative
Sponsor
pharmaand GmbH
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04676334CT.gov CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | — | Completed | — | — | — |
NCT04253262CT.gov A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03413995CT.gov Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations | — | Completed | — | — | — |
NCT03442556CT.gov Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rucaparib (this asset) | pharmaand GmbH | P3 | B · 56 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Prednisone | Mayo Clinic | P4 | BB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Carboplatin | Case Comprehensive Cancer Center | P3 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Rucaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peritoneum Cancer | — | P3 | BB · 66 |
| Ovarian Cancer | — | P3 | B · 61 |
| Ovarian Carcinoma | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rucaparib in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rucaparib-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →